Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial in parallel groups which evaluates the clinical efficacy and safety of immunotherapy with the purified major allergen Cup a 1, in patients with moderate/severe allergic rhino conjunctivitis with or without controlled asthma, sensitized to Cupressaceae
CompletedCTIS2024-519527-14-00
Diater Laboratorio De Diagnostico Y Aplicaciones Terapeuticas S.A.Allergic rhinoconjunctivitis
Start: 2022-06-09End: 2025-05-07Target: 150Updated: 2024-12-19